Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Keros Therapeutics Inc (NASDAQ: KROS) closed at $17.18 down -1.72% from its previous closing price of $17.48. In other words, the price has decreased by -$1.72 from its previous closing price. On the day, 0.79 million shares were traded. KROS stock price reached its highest trading level at $17.58 during the session, while it also had its lowest trading level at $17.1.
Ratios:
For a deeper understanding of Keros Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.01. For the most recent quarter (mrq), Quick Ratio is recorded 29.86 and its Current Ratio is at 29.86. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $26. On June 10, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $18.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 15 ’25 when Pontifax Management 4 G.P. (20 sold 4,787,331 shares for $17.75 per share. The transaction valued at 84,975,125 led to the insider holds 0 shares of the business.
ADAR1 Capital Management, LLC sold 5,389,264 shares of KROS for $95,659,436 on Oct 15 ’25. The 10% Owner now owns 0 shares after completing the transaction at $17.75 per share. On Sep 12 ’25, another insider, Rovaldi Christopher, who serves as the Affiliate of the company, bought 85,306 shares for $15.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 523407072 and an Enterprise Value of -152635936. As of this moment, Keros’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.14. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.12 while its Price-to-Book (P/B) ratio in mrq is 0.99. Its current Enterprise Value per Revenue stands at -0.619 whereas that against EBITDA is -3.185.
Stock Price History:
The Beta on a monthly basis for KROS is 0.90, which has changed by -0.71933204 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is 7.55%, while the 200-Day Moving Average is calculated to be 22.01%.
Shares Statistics:
For the past three months, KROS has traded an average of 893.86K shares per day and 1325770 over the past ten days. A total of 40.63M shares are outstanding, with a floating share count of 28.40M. Insiders hold about 6.77% of the company’s shares, while institutions hold 106.64% stake in the company. Shares short for KROS as of 1763078400 were 6781420 with a Short Ratio of 7.59, compared to 1760486400 on 3817848. Therefore, it implies a Short% of Shares Outstanding of 6781420 and a Short% of Float of 42.990002.
Earnings Estimates
A comprehensive evaluation of Keros Therapeutics Inc (KROS) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.45 and low estimates of -$0.65.
Analysts are recommending an EPS of between $2.68 and $2.1 for the fiscal current year, implying an average EPS of $2.33. EPS for the following year is -$2.89, with 8.0 analysts recommending between -$0.74 and -$4.71.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $253.68M, while the lowest revenue estimate was $234.26M, resulting in an average revenue estimate of $246.08M. In the same quarter a year ago, actual revenue was $3.55M
